IDEF Educational Series Experience EBGLYSS™ lebrikizumab lbkz A New Treatment Option

(32:17)

IDEF Educational Series Treatment Innovation Discover ZORYVE roflumilast 0 15% for a new indicatio

(1:34)

IDEF Educational Series Clinical Updates for WINLEVI® clascoterone Cream 1%

(1:1:6)

IDEF Educational Series Advance your Knowledge An Oral Treatment for Severe Alopecia Areata

(42:38)

IDEF Educational Series Considering the Needs of Patients With Refractory Moderate to Severe Atopic

(46:7)

IDEF Educational Series The Latest Approved Indication for COSENTYX® secukinumab

(30:33)

IDEF Educational Series Beyond the Surface Exploring Topical Roflumilast

(1:54:55)

IDEF Educational Series Opzelura for Vitiligo Achieving and Maintaining Repigmentation

(1:8:6)

IDEF Educational Series The IL 31 Neuroimmune Pathway The Key to PN

(47:9)

IDEF Educational Series: How to Navigate the Changing Landscape of Dermatology and Industry

(52:25)

IDEF Educational Series Webinar New Approaches in the Treatment of Mild to Severe Acne with AviClea

(59:29)

IDEF Educational Series Experience EBGLYSS lebrikizumab lbkz A New Treatment Option

(51:4)

IDEF Educational Series Webinar The Art of Clear Skin Exploring Dermo Cosmetics as a Key Player

(49:35)

IDEF Educational Series Mild to Moderate Atopic Dermatitis Burden of Disease and a Topical Pathway

(54:27)

IDEF Educational Series Raising the Bar Exploring Higher level Endpoints from a Head to Head Study

(44:1econd)

IDEF Educational Series Mild to Moderate Atopic Dermatitis Burden of Disease and a Topical Pathway

(1:59)

IDEF Educational Series OPZELURA in Practice Vitiligo Real – World Case Studies

(51:21)

IDEF Educational Series Exploring A Neuroimmune Pathway Underlying the Pathophysiology of Prurigo N

(54:19)

IDEF Educational Series Webinar Step into Possibility Explore Olumiant 2 year Data

(1:6:34)

IDEF Educational Series Get to Know UCB The Underdog That’s Taking Over Immuno Dermatology

(56:53)